Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

SARS-CoV-2 ORF10 degrades mitochondrial antiviral signaling protein to suppress immune response

A novel mechanism by which SARS-CoV-2 inhibits the innate immune response; that is, ORF10 induces mitophagy-mediated MAVS degradation by binding to NIX.

5 Dec 2021

Quantum mechanical model offers insights into SARS-CoV-2 evolution

Researchers used an ab initio full quantum mechanical model to characterize the spike protein RBD interactions with host cells and gain mechanistic insights into SARS-CoV-2 evolution.

3 Dec 2021

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

A recent study reports neutralizing efficacy for a fused peptide-antibody molecule against SARS-CoV-2, providing hope that therapeutic neutralizing antibodies may soon be available.

3 Dec 2021

Green seaweed extract exhibits anti-SARS-CoV-2 activity in vitro

Researchers investigate the antiviral activities of SSPS extracted from green seaweed Ulva sp. to demonstrate the anti-SARS-CoV-2 activity of ulvans.

2 Dec 2021

New bioinformatics method for viral sgRNA analysis

A recent study discusses a bioinformatics method to help identify and explore sgRNAs uncovered in next-generation sequencing data.

2 Dec 2021

Impact of SARS-CoV-2 infection on testis function

A study published in the journal Nature Reviews Urology discusses the impact of coronavirus disease 2019 (COVID-19) on male fertility.

2 Dec 2021

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Researchers from Academia Sinica in Taiwan have been investigating new antibodies that could have strong effects against SARS-CoV-2 infection.

2 Dec 2021

Impact of engineered ACE2-Fc on SARS-CoV-2 infection

Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.

1 Dec 2021

Structure function analysis of potent antibodies against Beta SARS-CoV-2 variant

A team of researchers from UK and US institutions created a large panel of mAbs derived from memory B cells of convalescent Beta subjects to better understand the antigenic landscape of Beta.

1 Dec 2021

Impact of SARS-CoV-2 on oral health

New research examined SARS-CoV-2 and its impact on oral health and suggests that survival against the infection may be partially dependent on such factors.

1 Dec 2021

Role of interferon type I-driven responses associated with disease control in COVID-19

New research suggests that treatment with type I interferons in the early stage of COVID-19 may supress disease progression by limiting SARS-CoV-2 in hosts.

1 Dec 2021

Structure-guided virtual screening identifies novel SARS-CoV-2 Mpro inhibitors

A new paper deals with the identification of an antiviral compound that could help in developing additional drugs to help fight COVID-19.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

Glycosylation and disulfide bonding profile of SARS-CoV-2 spike glycoprotein

Researchers found that virus-like particles produced by co-expression of SARS-CoV-2 S, membrane, envelope, and nucleocapsid proteins contain S glycoproteins, which are modified by complex carbohydrates.

29 Nov 2021

Extended host range for SARS-CoV-2 variants of concern

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

29 Nov 2021

Study finds atazanavir inhibits main SARS-CoV-2 protease

Research shows that ATV has different antiviral activity compared to PAXLOVID™, encouraging further research.

29 Nov 2021

Immunity found 6 months after SARS-CoV-2 infection in children

A new study suggests that infection-induced antibodies persist, providing protection for at least six months.

29 Nov 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known as interferon, allowing for the mitigation of coronavirus disease (COVID-19) severity. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

28 Nov 2021